首页> 外文期刊>Molecular cancer research: MCR >Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis.
【24h】

Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis.

机译:胸腺嘧啶靶向核因子-{kappa} B激活途径:在抗凋亡基因产物的抑制和凋亡增强中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Thymoquinone (TQ), derived from the medicinal plant Nigella sativa, exhibits antiinflammatory and anticancer activities through mechanism(s) that is not fully understood. Because numerous effects modulated by TQ can be linked to interference with the nuclear factor-kappaB (NF-kappaB) signaling, we investigated in detail the effect of this quinone on NF-kappaB pathway. As examined by DNA binding, we found that TQ suppressed tumor necrosis factor-induced NF-kappaB activation in a dose- and time-dependent manner and inhibited NF-kappaB activation induced by various carcinogens and inflammatory stimuli. The suppression of NF-kappaB activation correlated with sequential inhibition of the activation of IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 phosphorylation, p65 nuclear translocation, and the NF-kappaB-dependent reporter gene expression. TQ specifically suppressed the direct binding of nuclear p65 and recombinant p65 to the DNA, and this binding was reversed by DTT. However, TQ did not inhibit p65 binding to DNA when cells were transfected with the p65 plasmid containing cysteine residue 38 mutated to serine. TQ also down-regulated the expression of NF-kappaB-regulated antiapoptotic (IAP1, IAP2, XIAP Bcl-2, Bcl-xL, and survivin), proliferative (cyclin D1, cyclooxygenase-2, and c-Myc), and angiogenic (matrix metalloproteinase-9 and vascular endothelial growth factor) gene products. This led to potentiation of apoptosis induced by tumor necrosis factor and chemotherapeutic agents. Overall, our results indicate that the anticancer and antiinflammatory activities previously assigned to TQ may be mediated in part through the suppression of the NF-kappaB activation pathway, as shown here, and thus may have potential in treatment of myeloid leukemia and other cancers. (Mol Cancer Res 2008;6(6):1059-70).
机译:源自药用植物Nigella sativa的胸腺醌(TQ)通过尚未完全了解的机理表现出抗炎和抗癌活性。由于受TQ调节的许多效应都可能与对核因子-kappaB(NF-kappaB)信号的干扰有关,因此我们详细研究了这种醌对NF-kappaB途径的影响。通过DNA结合检查,我们发现TQ以剂量和时间依赖性方式抑制肿瘤坏死因子诱导的NF-κB活化,并抑制各种致癌物和炎性刺激物诱导的NF-κB活化。 NF-kappaB激活的抑制与依次抑制IkappaBalpha激酶,IkappaBalpha磷酸化,IkappaBalpha降解,p65磷酸化,p65核易位以及NF-kappaB依赖的报告基因表达的抑制有关。 TQ特异性抑制了核p65和重组p65与DNA的直接结合,这种结合被DTT逆转。但是,当用含有突变为丝氨酸的半胱氨酸残基38的p65质粒转染细胞时,TQ不会抑制p65与DNA的结合。 TQ还下调了NF-κB调节的抗凋亡蛋白(IAP1,IAP2,XIAP Bcl-2,Bcl-xL和survivin),增殖性蛋白(cyclin D1,环氧合酶2和c-Myc)的表达和血管生成(基质金属蛋白酶9和血管内皮生长因子)基因产物。这导致由肿瘤坏死因子和化学治疗剂诱导的凋亡的增强。总体而言,我们的结果表明,先前分配给TQ的抗癌和抗炎活性可能部分通过抑制NF-κB活化途径来介导,如此处所示,因此可能在治疗髓样白血病和其他癌症中具有潜力。 (Mol Cancer Res 2008; 6(6):1059-70)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号